volume 192, issue 6, P2643-2650 2014
DOI: 10.4049/jimmunol.1302076
View full text
Jinhong Wu, Jinwook Shin, Danli Xie, Hongxia Wang, Jimin Gao, Xiao-Ping Zhong

Abstract: Development of effective immune therapies for cancer patients requires better understanding of hurdles that prevent the generation of effective anti-tumor immune responses. Administration of α-galactosylceramide (α-GalCer) in animals enhances anti-tumor immunity via activation of the invariant natural killer T (iNKT) cells. However, repeated injections of α-GalCer result in long-term unresponsiveness or anergy of iNKT cells, severely limiting its efficacy in tumor eradication. The mechanisms leading to iNKT c…

expand abstract